[go: up one dir, main page]

AR132886A1 - Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano - Google Patents

Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano

Info

Publication number
AR132886A1
AR132886A1 ARP240101448A ARP240101448A AR132886A1 AR 132886 A1 AR132886 A1 AR 132886A1 AR P240101448 A ARP240101448 A AR P240101448A AR P240101448 A ARP240101448 A AR P240101448A AR 132886 A1 AR132886 A1 AR 132886A1
Authority
AR
Argentina
Prior art keywords
nanoemulsion
human papillomavirus
against human
vaccines against
adjuvant compositions
Prior art date
Application number
ARP240101448A
Other languages
English (en)
Inventor
Patrick L Ahl
John Gaspar
Julie M Skinner
William J Smith
Randal J Soukup
Nicole Lea Sullivan
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of AR132886A1 publication Critical patent/AR132886A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/10—Terrestrial scenes
    • G06V20/13—Satellite images
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G06N20/20—Ensemble learning
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N3/00—Computing arrangements based on biological models
    • G06N3/02—Neural networks
    • G06N3/08—Learning methods
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N5/00—Computing arrangements using knowledge-based models
    • G06N5/01—Dynamic search techniques; Heuristics; Dynamic trees; Branch-and-bound
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00—Arrangements for image or video recognition or understanding
    • G06V10/40—Extraction of image or video features
    • G06V10/62—Extraction of image or video features relating to a temporal dimension, e.g. time-based feature extraction; Pattern tracking
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/50—Context or environment of the image
    • G06V20/52—Surveillance or monitoring of activities, e.g. for recognising suspicious objects
    • G06V20/54—Surveillance or monitoring of activities, e.g. for recognising suspicious objects of traffic, e.g. cars on the road, trains or boats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V10/00—Arrangements for image or video recognition or understanding
    • G06V10/70—Arrangements for image or video recognition or understanding using pattern recognition or machine learning
    • G06V10/82—Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Landscapes

  • Engineering & Computer Science (AREA)
  • Theoretical Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Software Systems (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Multimedia (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Computational Linguistics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Astronomy & Astrophysics (AREA)

Abstract

La presente divulgación proporciona, entre otras cosas, una composición de vacuna que incluye un adyuvante de nanoemulsión de escualeno (SNE) y partículas similares a virus del HPV (VLP) de al menos un tipo del papilomavirus humano (HPV) seleccionado del grupo que consiste en los tipos del HPV: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73 y 82.
ARP240101448A 2023-06-09 2024-06-06 Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano AR132886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202363507269P 2023-06-09 2023-06-09

Publications (1)

Publication Number Publication Date
AR132886A1 true AR132886A1 (es) 2025-08-06

Family

ID=93745913

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101448A AR132886A1 (es) 2023-06-09 2024-06-06 Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano

Country Status (7)

Country Link
US (1) US20240408188A1 (es)
AR (1) AR132886A1 (es)
AU (1) AU2024284242A1 (es)
CO (1) CO2025017116A2 (es)
MX (1) MX2025014793A (es)
TW (1) TW202513091A (es)
WO (1) WO2024254226A1 (es)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
AU4270196A (en) 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US5820870A (en) 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7410795B2 (en) 2002-12-23 2008-08-12 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
CN100506999C (zh) 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
RU2373219C2 (ru) 2004-03-24 2009-11-20 Мерк энд Ко. Инк. Оптимизированная экспрессия hpv 52 l1 в дрожжах
CA2566355C (en) 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
MX2007013472A (es) 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
US20090285881A1 (en) 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
US20100055169A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20100076055A1 (en) 2008-04-16 2010-03-25 Abbott Laboratories Cationic Lipids and Uses Thereof
US20100055168A1 (en) 2008-04-16 2010-03-04 Abbott Laboratories Cationic lipids and uses thereof
US20090263407A1 (en) 2008-04-16 2009-10-22 Abbott Laboratories Cationic Lipids and Uses Thereof
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
WO2010021865A1 (en) 2008-08-18 2010-02-25 Merck Sharp & Dohme Corp. Novel lipid nanoparticles and novel components for delivery of nucleic acids
US20100063135A1 (en) 2008-09-10 2010-03-11 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
WO2010030730A1 (en) 2008-09-10 2010-03-18 Abbott Laboratories Polyethylene glycol lipid conjugates and uses thereof
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
US8952955B2 (en) 2009-06-17 2015-02-10 Sharp Kabushiki Kaisha Display driving circuit, display device and display driving method
WO2011022460A1 (en) 2009-08-20 2011-02-24 Merck Sharp & Dohme Corp. Novel cationic lipids with various head groups for oligonucleotide delivery
BR112012015755B1 (pt) 2009-12-23 2021-06-22 Novartis Ag Lipídeo furtivo, e composição
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
CN108042799A (zh) * 2010-07-06 2018-05-18 诺华股份有限公司 阳离子水包油乳液
US9669097B2 (en) 2010-09-20 2017-06-06 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
CN103796639B (zh) * 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems

Also Published As

Publication number Publication date
US20240408188A1 (en) 2024-12-12
MX2025014793A (es) 2026-01-07
WO2024254226A1 (en) 2024-12-12
AU2024284242A1 (en) 2026-01-22
CO2025017116A2 (es) 2025-12-19
TW202513091A (zh) 2025-04-01

Similar Documents

Publication Publication Date Title
DOP2022000168A (es) Vacuna contra hpv
AR041880A1 (es) Composicion inmunogena
AR064009A1 (es) Metodo de inmunizacion contra los 4 serotipos del dengue
PE20061287A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
JP2016155867A5 (es)
CO6270337A2 (es) Vacuna viva avirulenta de mycoplama hyopneumoniae con adyuvante
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR075484A1 (es) Pestivirus quimericos
PH12017501257A1 (en) Foot-and-mouth disease vaccine
PE20230349A1 (es) Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas
MX2023012530A (es) Composición y metodos de vacuna adyuvada.
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
AR132886A1 (es) Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano
MX2020010410A (es) Empaquetado de oligonucleotidos en particulas similares a virus.
CL2013002723A1 (es) Metodo de produccion de una particula semejante a virus (vlp) de alfavirus salmonido (sav) en celulas de insecto.
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
CU24682B1 (es) Una composición de vacuna multivalente compuesta por una mezcla de antígenos provenientes de virus de polio y rotavirus inactivados
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
MX2024002144A (es) Nueva nanoparticula lipidica termostable y metodos de uso de la misma.
AR126708A1 (es) Vacuna para el vph
CR20250083A (es) Proteína g antirrábica y sus usos
AR120296A1 (es) Vacuna de partículas de virus de tipo chikungunya y sus métodos de uso
WO2021021753A3 (en) A porcine circovirus type 2 (pcv2) vaccine
MX2012002630A (es) Regimen de inmunizacion por sensibilizacion-refuerzo heterologa contra el virus de la lengua azul.